{"entity":{"id":"paper-cohen-cancerseek-multi-analyte-blood-test-science-2018","kind":"paper","name":"Detection and localization of surgically resectable cancers with a multi-analyte blood test","aka":[],"tldr":"CancerSEEK, a blood test reading eight proteins and mutations in free DNA, found a median 70% of 1,005 non-spread cancers of eight types, including pancreatic cancer, and pointed to the organ involved in most cases.","summary":"A blood test assessing circulating protein levels and mutations in cell-free DNA was applied to 1,005 patients with non-metastatic, clinically detected cancers of the ovary, liver, stomach, pancreas, oesophagus, colorectum, lung or breast. CancerSEEK tests were positive in a median of 70% of the eight cancer types, with sensitivities of 69 to 98% for the five types with no screening test for average-risk individuals (ovary, liver, stomach, pancreas, oesophagus). Specificity exceeded 99% with 7 of 812 healthy controls positive, and the test localised the cancer to a small number of anatomical sites in a median 83% of patients.","asOf":"2026-09-24","links":[{"label":"Cohen et al., Science 2018: CancerSEEK in 1,005 patients with eight cancer types","url":"https://doi.org/10.1126/science.aar3247"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/29348365/"}],"tags":[],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":["mced","liquid-biopsy","proteomics"],"targets":[],"drugs":["caris-mi-cancer-seek"],"companies":[],"institutions":["johns-hopkins"],"pathways":[],"terms":["ctdna","cfdna"],"trials":[],"people":["bert-vogelstein","nickolas-papadopoulos","kenneth-kinzler"],"bottlenecks":[],"keyPapers":[],"journals":["science"],"dependsOn":[],"notes":[],"journal":"Science","year":2018,"doi":"10.1126/science.aar3247","pmid":"29348365","authors":"Cohen JD, Li L, Wang Y, et al.","paperType":"observational","findings":["Median 70% sensitivity across eight cancer types at over 99% specificity.","Pancreas among the five types at 69 to 98% sensitivity.","Tissue of origin localised in a median 83% of positives."],"whatItMeans":"The proof of principle for multi-cancer blood tests that include pancreas; the sensitivity figures come from known cancers, not from screening.","caveats":["Case-control design with clinically detected cancers.","Stage I sensitivity is much lower than the headline figure."],"changedPractice":false,"participants":1817},"route":"/key-papers/paper-cohen-cancerseek-multi-analyte-blood-test-science-2018/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"},{"id":"proteomics","kind":"technology","name":"Proteomics & phosphoproteomics","route":"/technologies/proteomics/"}],"drug":[{"id":"caris-mi-cancer-seek","kind":"drug","name":"MI Cancer Seek","route":"/drugs/caris-mi-cancer-seek/"}],"institution":[{"id":"johns-hopkins","kind":"institution","name":"Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center","route":"/institutions/johns-hopkins/"}],"term":[{"id":"cfdna","kind":"term","name":"Cell-free DNA (cfDNA)","route":"/terms/cfdna/"},{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"},{"id":"detect-a-study","kind":"term","name":"DETECT-A: a blood test plus PET-CT to screen 10,006 women with no symptoms","route":"/terms/detect-a-study/"}],"person":[{"id":"bert-vogelstein","kind":"person","name":"Bert Vogelstein","route":"/people/bert-vogelstein/"},{"id":"kenneth-kinzler","kind":"person","name":"Kenneth W. Kinzler","route":"/people/kenneth-kinzler/"},{"id":"nickolas-papadopoulos","kind":"person","name":"Nickolas Papadopoulos","route":"/people/nickolas-papadopoulos/"}],"journal":[{"id":"science","kind":"journal","name":"Science","route":"/journals/science/"}]}}